ESMO 2018 | Treatment landscape for HCC

Arndt Vogel, MD, PhD, of Hannover Medical School, Hannover, Germany, outlines the progress made in hepatocellular carcinoma (HCC) treatment over the past few years, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Prof. Vogel expresses caution about SIRT Y-90, which has not had favorable outcomes for HCC patients progressing on local therapies. However, in the past two years, there has been an influx of new agents, particularly in the field of immunotherapy, with positive trial results.